Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis

Nephrology

Volumn 15, Issue 2, 2010, Pages 178-183

  Garcia Fernandez, Nuria ^a   Echeverria, Aitziber ^a   Sanchez Ibarrola, Alfonso ^a   PÁramo, José Antonio ^a   Coma Canella, Isabel ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cytokines; Haemodialysis; Iron; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; CD11B ANTIGEN; CD18 ANTIGEN; FERRIC HYDROXIDE SUCROSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MALONALDEHYDE; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ANTIGEN EXPRESSION; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; MALE; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ACETYLCYSTEINE; AGED; ANTIGENS, CD11B; ANTIGENS, CD18; ANTIOXIDANTS; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 77749324150     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01174.x     Document Type: Article

References (36)

1. Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr. Opin. Nephrol. Hypertens. 2008 17 : 560 565.
2. Pawlak K, Naumnik B, Brzosko S, Pawlak D, Myśliwiec M. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in hemodialysis patients. Am. J. Nephrol. 2004 24 : 154 161.
3. Himmelfarb J. Oxidative stress in hemodialysis. Contrib. Nephrol. 2008 161 : 132 137.
4. Todeschini M, Macconi D, García-Fernandez N et al. Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am. J. Kidney Dis. 2002 40 : 783 793.
5. Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin. J. Am. Soc. Nephrol. 2006 1 (Suppl 1 S24 31.
6. Rooyakers TM, Stroes ES, Kooistra MP et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur. J. Clin. Invest. 2002 32 : 9 16.
7. Bishu K, Agarwal R, Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin. J. Am. Soc. Nephrol. 2006 1 (Suppl 1 S19 23.
8. Kartikasari AE, Visseren FL, Marx JJ et al. Intracellular labile iron promotes firm adhesion of human monocytes to endothelium under flow and transendothelial migration Iron and monocyte-endothelial cell interactions. Atherosclerosis 2008. DOI: 10.1016/j.atherosclerosis.2008.12.031.
9. Guz G, Glorieux GL, De Smet R et al. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. Nephrol. Dial. Transplant. 2006 21 : 2834 2840.
10. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 2000 11 : 530 538.
11. Schiesser D, Binet I, Tsinalis D et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete hemodialysis patients. Nephrol. Dial. Transplant. 2006 21 : 2841 2845.
12. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002 61 : 1830 1839.
13. Altman DG, Schulz KF, Moher D et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann. Intern. Med. 2001 134 : 663 694. (Pubitemid 32322245)
14. Moreno C, Merino J, Ramírez N, Echeverría A, Pastor F, Sánchez-Ibarrola A. Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14. Microbes Infect. 2004 6 : 990 995.
15. Bergstrom J, Whele B. No change in corrected beta2-microglobulin concentration after cuprophan hemodialysis. Lancet 1987 1 : 628 629.
16. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007 27 : 343 350.
17. Fiorillo C, Oliviero C, Rizzuti G, Nediani C, Pacini A, Nassi P. Oxidative stress and antioxidant defenses in renal patients receiving regular hemodialysis. Clin. Chem. Lab. Med. 1998 36 : 149 153.
18. Yavuz O, Bicik Z, Cinar Y, Guney Y, Guler S. The effect of different dialysis membranes on oxidative stress selenium status. Clin. Chim. Acta 2004 346 : 153 160.
19. Stefánsson BV, Haraldsson B, Nilsson U. Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection. Free Radic. Biol. Med. 2008 45 : 1302 1307.
20. Cavdar C, Temiz A, Yenicerioglu Y, Calis S et al. The effects of intravenous iron treatment on oxidant stress and erythrocytes deformability in hemodialysis patients. Scand. Urol. Nephrol. 2003 37 : 77 82.
21. Driss F, Vrtovsnik F, Katsahian S et al. Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients. Nephron Clin. Pract. 2005 99 : 63 7.
22. Kelly GS. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 1998 3 : 114 127.
23. Trimarchi H, Mongitore MR, Baglioni P et al. N-acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients - a pilot study. Clin. Nephrol. 2003 59 : 441 446.
24. Agarwal R, Vasavada N, Nadine G, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004 65 : 2279 2289.
25. Leehey DJ, Palubiak DJ, Chebrolu S, Agarwal R. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol. Dial. Transplant. 2005 20 : 135 140.
26. Friedrich B, Alexander D, Janessa A, Häring HU, Lang F, Risler T. Acute effects of hemodialysis on cytokine transcription profiles: evidence for C-reactive protein-dependency of mediator induction. Kidney Int. 2006 70 : 2124 2130.
27. Kawabata K, Nagake Y, Shikata K, Makino H, Ota Z. The changes of Mac-1 and L-selectin expression on granulocytes and soluble L-selectin level during hemodialysis. Nephron 1996 73 : 573 579.
28. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb. Haemost. 2007 97 : 714 721.
29. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003 64 : 572 578.
30. Denis CV. Molecular and cellular biology of von Willebrand Factor. Int. J. Hematol. 2002 75 : 3 8.
31. Vischer UM, Jornot L, Wollheim CB, Theler JM. Reactive oxigen intermediates induce regulated secretion of von Willebrand Factor from cultures human vascular endothelial cells. Blood 1995 85 : 3164 3172.
32. Leeuwenberg JF, Smeets EF, Neefjes JJ et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992 77 : 543 549.
33. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003 170 : 191 203.
34. Borawski J, Gozdzikiewicz J, Abramowicz P, Beata Naumnik B, Mysliwiec M. Endotelial injury markers with high-dose intravenous iron therapy in renal failure. Clin. Appl. Thromb. Hemost. 2004 10 : 403 406.
35. Nandate K, Masanori O, Tamura M, Kawasaki T, Sata T, Shigematsu A. N-Acetyl Cysteine attenuated endotoxin-induced adhesion molecule expression in human whole blood. Anesth. Analg. 2005 100 : 1453 1457.
36. Radomska-Lesniewska DM, Sadowska AM, Van Overveld FJ, Demkow U, Zielinski J, de Backer WA. Influence of N-Acetylcysteine on ICAM-1 expression and IL-8 release from endothelial and epithelial cells. J. Physiol. Pharmacol. 2006 57 (Suppl 4 325 334.